Indian Journal of Pharmacology最新文献

{"title":"Hemoglobin estimation by the classical method should be adhered to for understanding anemia following lead exposure: Old is gold.","authors":"Sumanpreet Kaur, Deepak Kumar, Rajasri Bhattacharyya, Dibyajyoti Banerjee","doi":"10.4103/ijp.ijp_605_24","DOIUrl":"10.4103/ijp.ijp_605_24","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 3","pages":"200-201"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A simple patch test (empty tablet cover patch test) demonstrating ornidazone as offending agent in a patient of fixed drug eruption: Report of a clinical case, a new modified technique and systematic review of literature.","authors":"R Balamurugan, Phulen Sarma, Prabhakaran Nagendran, Deepthi Slesser Nicodemus, Sushil Sharma","doi":"10.4103/ijp.ijp_708_22","DOIUrl":"10.4103/ijp.ijp_708_22","url":null,"abstract":"<p><p>A 49-year-old male presented with the complaints of sudden-onset redness and watering of both the eyes following the intake of fixed drug combination of ofloxacin-ornidazole for diarrhea. Following this, he developed redness of both the lips and blisters in the upper lip. He also developed erythematous macules in the medial aspects of the right lower thigh and ventral aspects of the right leg. Ocular examination showed conjunctival redness with diffuse corneal punctate epithelial erosions in both the eyes. The patient had a similar history affecting the same region 1 year back following the intake of the same combination medicine. To find out the specific inciting agent and owing to unavailability of Finn chamber, we developed a new modified skin patch test using empty tablet cover with three chambers, incorporated with ornidazole, Vaseline (petroleum jelly), and ofloxacin, respectively, and applied on the healed affected lesions. Modified patch test was positive for ornidazole at 48 h. Ornidazole-induced fixed drug eruption (FDE) affecting cornea is a rare and unique in our case report. The patient was then educated about the offending medication and advised to avoid in the future. We also conducted a systematic review of FDEs associated with ornidazole exposure. We searched PubMed and Google Scholar with specific keywords to finally retrieve 14 case reports of ofloxacin induced FDEs, which were further reviewed.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 3","pages":"179-186"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardioprotective potential of shikonin in cardiac hypertrophy is mediated through PKM2/c-Myc/PTBP1/HIF-1α signaling pathway.","authors":"Mohd Rihan, Shyam Sunder Sharma","doi":"10.4103/ijp.ijp_742_24","DOIUrl":"10.4103/ijp.ijp_742_24","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic sympathetic stress contributes significantly to the cardiac hypertrophy (CH) development. Currently, several pharmacological agents and surgical options are available for the treatment of CH. However, available treatment options are associated with side effects and surgical complications. The published reports indicated the PKM2 substantial role in numerous illnesses. Furthermore, the effect of shikonin (SK), a nonselective PKM2 inhibitor, on PKM2/c-Myc/PTBP1/HIF-1α signaling in the CH model has never been explored. Thus, in this study, we explore the effect of SK on the PKM2-mediated c-Myc/PTBP1/HIF-1α signaling pathway in isoproterenol (ISO)-induced CH.</p><p><strong>Materials and methods: </strong>The preclinical rat model of pathological CH was developed by subcutaneous (s.c.) administration of ISO (5 mg/kg/day) over 14 days. ISO-treated rats were orally received SK (2 and 4 mg/kg/day) for a period of 14 days. After all treatment completion, animals were anesthetized for electrocardiogram (ECG), blood pressure, and ventricular function recording. Afterward, animal blood samples were isolated, and then animals were sacrificed for further molecular and histopathology studies.</p><p><strong>Results: </strong>Fourteen days treatment of SK showed significant improvement in ECG, fibrosis, inflammation, and cardiac function. Moreover, PKM2, PTBP1, c-Myc, and HIF-1α expressions were upregulated, while PKM1 expression was downregulated in ISO-treated rats, which was reversed by SK treatment in ISO-induced CH rats.</p><p><strong>Conclusion: </strong>Thus, our results demonstrated that SK modulates the PKM2/c-Myc/PTBP1/HIF-1α pathway mediated by PKM2 inhibition, which might be responsible for SK-mediated cardioprotection in ISO-induced CH.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 3","pages":"126-133"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute accidental methotrexate poisoning: Fatal consequences - An Indian experience.","authors":"Mauli M Shah, Priya K Ghoghara, Shree Dhanani, Keyur Patel, Pragya A Nair","doi":"10.4103/ijp.ijp_363_24","DOIUrl":"10.4103/ijp.ijp_363_24","url":null,"abstract":"<p><p>Methotrexate (MTX) is a versatile drug used in various fields, including oncology and rheumatology, acting by inhibitory effects on DNA synthesis and cellular replication. While low-dose MTX is a first-line treatment for rheumatoid arthritis and psoriasis, overdose or incorrect dosing can lead to severe toxicity. We present three cases of accidental MTX poisoning, highlighting the diverse clinical manifestations and challenges in management. Patients presented with fever, weakness, mucocutaneous lesions, and pancytopenia, necessitating intensive care and supportive treatment. These cases underscore the importance of proper dosing, patient education, and pharmacist vigilance to prevent medication errors. Heightened awareness among clinicians is crucial to promptly recognize and manage MTX toxicity, ensuring the safe and effective use of this valuable therapeutic agent. Further research is needed to optimize dosing strategies and enhance safety measures for MTX administration.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 3","pages":"196-199"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted active surveillance of branded generic deferasirox in pediatric thalassemia patients in a tertiary care hospital of India: A pharmacovigilance study.","authors":"Mousumee Panigrahi, Trupti Rekha Swain, Rabindra Kumar Jena, Ashutosh Panigrahi, Nishant Debta","doi":"10.4103/ijp.ijp_88_23","DOIUrl":"10.4103/ijp.ijp_88_23","url":null,"abstract":"<p><strong>Introduction: </strong>Deferasirox is a newer oral iron chelator which needs to be given for at least 1 year to see a significant decrease in serum ferritin level in thalassemia patients with chronic iron overload. This study aimed to assess the safety profile of branded generic deferasirox in pediatric thalassemia cases, as it has not been studied in eastern India, especially in real-world settings.</p><p><strong>Subjects and methods: </strong>It was an observational hospital-based study in a government tertiary care teaching hospital where branded generic deferasirox is distributed free of cost to patients. One hundred and seventy-four patients were included. Safety assessment was done through active questioning about the symptoms starting after deferasirox therapy and through laboratory parameters and clinical examination.</p><p><strong>Results: </strong>Sixty percent of patients developed adverse drug reactions (ADRs) with deferasirox during the 1-year follow-up. ADRs were more common in males than females. The highest number of ADRs was related to the gastrointestinal and hepatobiliary system. The ADRs were either mild or moderate. Compliance and number of ADRs were found to be inversely correlated.</p><p><strong>Conclusion: </strong>ADRs of deferasirox are acceptable looking at the benefits. Regular monitoring and management of ADRs will facilitate patient compliance. However, healthcare professionals need to be alert while prescribing this drug and report any ADR, even if it is not labeled. This study found increased serum lipase and mouth ulcer as adverse effects, which are not yet labeled. These can be signals for further analysis by regulatory authorities.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 2","pages":"77-82"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imatinib attenuates neurobehavioral deficits and hippocampal neuronal damage after global cerebral ischemia in gerbils.","authors":"Hina Lateef Nizami, Krishnamoorthy Srinivasan, Shyam Sunder Sharma","doi":"10.4103/ijp.ijp_726_23","DOIUrl":"10.4103/ijp.ijp_726_23","url":null,"abstract":"<p><strong>Abstract: </strong>Imatinib mesylate, a selective tyrosine kinase inhibitor, exhibited beneficial effects against various neurological diseases besides its anticancer activity. However, its effects on global cerebral ischemia in gerbils remain to be investigated. Global cerebral ischemia was induced by bilateral carotid artery occlusion (BCAO) in male Mongolian gerbils. Imatinib (3, 10, and 30 mg/kg BW) was administered intraperitoneally (i.p.) 30 min before BCAO. Imatinib (3 and 10 mg/kg) significantly ameliorated neurological deficits, locomotor hyperactivity, and cognitive deficits (Y-maze spontaneous alternations) at 4, 24, and 72 h, respectively, after reperfusion in gerbils. Imatinib caused reduction in neuronal cell death in CA1 hippocampal region of gerbils after BCAO and was associated with abrogation of elevated immunoreactivity of endoplasmic reticulum (ER) stress markers (GRP78 and CHOP). This study demonstrates the neuroprotective effect along with functional improvement by imatinib in global cerebral ischemia in gerbils that may be due to mitigation of ER stress.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 2","pages":"97-101"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the collective advantages of sodium-glucose cotransporter-2 inhibitors and GLP-1 analogs in addressing metabolic health issues linked to obese type 2 diabetes mellitus and related comorbidities.","authors":"Sulthan Al-Rashid, Monisha Prasad, Rajkapoor Balasubramanian, Naina Mohamed Pakkir Maideen","doi":"10.4103/ijp.ijp_559_24","DOIUrl":"10.4103/ijp.ijp_559_24","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 2","pages":"104-105"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of disease-modifying agents in ameliorating multiple sclerosis - A cross-sectional observational study.","authors":"Mamatha Jayachandran, Dhanya Sacheendran, Sanitha Kuriachan, Princy Louis Palatty, Greeshma C Ravindran","doi":"10.4103/ijp.ijp_493_23","DOIUrl":"10.4103/ijp.ijp_493_23","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) - A chronic inflammatory demyelinating disorder of the central nervous system is notorious for causing progressive neurological deterioration. This affects the quality of life of these patients and their productivity. Various oral and injectable disease-modifying drugs (DMDs) are available for the treatment of MS. In spite of availability of many drugs, the quality of life of these patients continues to be perturbing. The present study was undertaken to assess the effectiveness of common therapy in MS.</p><p><strong>Methods: </strong>A single-center cross-sectional study was conducted from 2020 to 2021. Seventy-one MS patients on DMDs were recruited. Relevant clinical details were collected from the electronic medical records, and a quality-of-life questionnaire was administered telephonically. Assessment of drugs being prescribed, treatment effectiveness, and adverse drug reactions were calculated as frequency and percentage.</p><p><strong>Results: </strong>Female cases were 64.8%. 77.5% were relapsing-remitting type of MS. The initial presenting complaints varied from visual disturbances in 28.16%, paresthesia in 25.35%, and ataxia in 21.12%. No relapse episodes were reported in 21.12% of cases. 33.8% faced physical disabilities and 9.9% cognitive disabilities. 2.81% cases opined that their quality of life is good.</p><p><strong>Conclusions: </strong>Drug therapy is beneficial in providing remission and reducing relapse rates in MS. DMDs are effective in reducing the debilitating symptoms and preventing the progression of the disease, when begun immediately after the diagnosis is made.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 2","pages":"90-96"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eyelid hyperpigmentation: Rare involvement following intake of common drug.","authors":"Ankur Singh, Shiva Manwatkar, Abhishek Abhinay, Rajniti Prasad","doi":"10.4103/ijp.ijp_565_24","DOIUrl":"10.4103/ijp.ijp_565_24","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 2","pages":"106-107"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of recombinant human parathyroid hormone and zoledronic acid on osteoblast gene expression using multifaceted approach: An in vitro study.","authors":"Vandana Dhiman, Sanjay Kumar Bhadada, Poonam Kanta, Gurjeet Kaur, Swati Bhat, Amanjit Bal, Naresh Sachdeva, Anil Bhansali, Devinder Kumar Dhawan, Ravi Pratap Barnwal, Gurpal Singh, Sudhaker Dhanwada Rao","doi":"10.4103/ijp.ijp_582_23","DOIUrl":"10.4103/ijp.ijp_582_23","url":null,"abstract":"<p><strong>Background: </strong>Bone is an endocrine organ that despite being inert in appearance constantly undergoes remodeling, in which wear and tear of bone cells occur. With more than two decades of clinical experience, the molecular mechanisms of anti-fracture drugs are not completely understood because they inhibit osteoclastic activity and differentiate the osteoblast cells. Recent studies suggest fundamentally different mechanisms of action for key anti-fracture drugs, bisphosphonates, and recombinant human parathyroid hormone (rhPTH) at the tissue level; however, their molecular basis of action has not been explored completely. Here, we showed the effect of varying concentrations of zoledronic acid (ZOL) and rhPTH on human osteogenic sarcoma cells (U2OS cells).</p><p><strong>Materials and methods: </strong>Cellular viability, mineralization, and osteogenic gene expressions were assessed to elucidate the effects of these two prototypic drugs with diametrically different mechanisms of action.</p><p><strong>Results: </strong>Cellular viability was not affected either by ZOL or rhPTH alone or in tandem treatments. Osteoblastic activity increased significantly with rhPTH followed by ZOL. Further, alkaline phosphatase activity increased significantly with tandem treatment of rhPTH followed by ZOL both at the mRNA and protein levels. Moreover, osteoblastic genes (COL1A1 and osteocalcin) were significantly modulated by sequential treatment with rhPTH followed by ZOL.</p><p><strong>Conclusions: </strong>We conclude that rhPTH (5 μg) treatment followed by ZOL (1 μM) showed the best anabolic or bone-forming effect. Our results warrant further research in assessing similar combinations of anti-fracture drugs, which augment osteogenesis to maximize their anabolic effects in preventing osteoporosis in susceptible individuals.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"57 2","pages":"69-76"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}